

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FACO Poster Session 2 * This is not charging session.			
FP2-1	How effective are psychological interventions for children with cancer and their parents? A multilevel meta-analysis and qualitative comparative analysis	Therdpong Thongseiratch	Child Development Unit, Department of Pediatrics, Prince of Songkla University, Thailand
FP2-2	Role of glycogenolysis in acquired temozolomide resistance through [Ca ²⁺]-dependent activation of Na,K-ATPase/ERK1/2 signaling in glioma	Junnan Xu	Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China
FP2-3	NOP14 promotes nasopharyngeal carcinoma progression by promoting ribosome biogenesis-associated mTOR2 activation and Akt stabilization	Bo-hua Kuang	Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China/Department of Experimental Research, Sun Yat-sen University Cancer Center, China
FP2-4	Predictive value of 18F-ML-10 PET/CT in early response evaluation of combination radiotherapy with cetuximab on nasopharyngeal carcinoma	Bingxin Gu	Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, China/Shanghai Engineering Research Center of Molecular Imaging Probes, China
FP2-5	Cost-effective analysis of concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma	Weiting Liao	Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China/West China Biomedical Big Data Center, Sichuan University, China
FP2-6	Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: A population-based study	Weikai Xiao	Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, China
FP2-7	Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or HER2-positive breast cancer	Junnan Xu	Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China
FP2-8	The molecular features differences between the better prognosis and the poorer prognosis triple-negative breast cancers	Junnan Xu	Department of Medical Oncology, Cancer Hospital of China Medical University, China
FP2-9	Predictive value of CD4 ⁺ /CD8 ⁺ ratio in patients with breast cancer receiving recombinant human thrombopoietin	Junnan Xu	Department of Medical University, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China/Key Laboratory of Liaoning Breast Cancer Research, China
FP2-10	Improvement of neurotoxicity outcome with Monosialotetrahexosylganglioside versus Trivitamin B in BC patients with Utidelone-induced Peripheral Neuropathy	Junnan Xu	Department of Medical Oncology, Cancer Hospital of China Medical University, China
FP2-11	Lymph node status guides taxane-based escalating and de-escalating chemotherapy in patients with early triple negative breast cancer	Sanxing Guo	Oncology Department, The First Affiliated Hospital of Zhengzhou University, China
FP2-12	The combination of NVP-BE235 and endostatin exerts synergistic anticancer activity against triple-negative breast cancer in vitro and in vivo	Xiaoshan Wang	Cancer Center, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China
FP2-13	Fulvestrant 500mg versus Exemestane in postmenopausal Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors (NSAI) in clinical practice	Yizhao Xie	Medical Oncology, Fudan University Shanghai Cancer Center, China
FP2-14	Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative metastatic breast cancer	Qiuji Wu	Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China
FP2-15	Concordance assessment of IBM Watson for oncology with MDT in patients with breast cancer	Junnan Xu	Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China/Key Laboratory of Liaoning Breast Cancer Research, China
FP2-16	Epigenetic silencing of the RBR-type E3 ubiquitin ligase RNF144A promotes breast cancer progression through enhancing HSPA2 oncoprotein stability	Yinlong Yang	Department of Breast Surgery, Fudan University Shanghai Cancer Center, China/Department of Oncology, Shanghai Cancer Center, Shanghai Medical College, Fudan University, China/Cancer Institute, Shanghai Cancer Center, Shanghai Medical College, Fudan University, China

Presentation No.	Presentation Title	Chair/Speaker's Name	Affiliation
FP2-17	Expression of LAPTM4B and loss of p27kip1 are correlated and predict poor prognosis in triple negative breast cancer	Xuelu Li	Department of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical University, China
FP2-18	Receptor conversion between primary and distant metastatic breast cancer	Weikai Xiao	Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, China
FP2-19	Postoperative micropapillary lung adenocarcinoma patients have higher rates of vascular cancer thrombi, bronchial invasion and positive ALK fusion protein	Shaomei Li	Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China
FP2-20	Plasma vitamin D level is an independent prognosis factor in small cell lung cancer patients treated with platinum plus etoposide as first-line chemotherapy	Xu Wang	Department of Medical Oncology, The First Hospital of Ji Lin University, China
FP2-21	EGFR tyrosine kinase inhibitor combined with synchronous or sequential chemotherapy for advanced NSCLC patients of gradual progression after first-line EGFR-TKI therapy: A randomized controlled study	Tianqing Chu	Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, China
FP2-22	Benefits of Etoposide maintenance therapy for patients with extensive SCLC who experienced PR/CR/SD after 4-6 cycles of first-line chemotherapy with etoposide plus cisplatin/carboplatin	Zhen He	Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China
FP2-23	Successful Return to Intended Oncologic Therapy (RIOT) improving overall survival in lung cancer patients with pathologic stage II and III: Evidence from the real world	Wei Dai	Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China
FP2-24	BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203a-DKK1	Zhang P. Panpan	Thoracic Surgery II, Peking University Cancer Hospital & Institute, China
FP2-25	Management of anlotinib-related adverse events in advanced non-small cell lung cancer: Experiences in ALTER-0303	Xiaoyan Si	Respiratory Diseases, Peking Union Medical College Hospital, China
FP2-26	Lymph node metastases in surgically resected NSCLC with solitary ground-glass opacities	Song Xu	Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, China
FP2-27	Impact of genetic alterations on outcomes of patients with stage I non-small cell lung cancer: An analysis of the cancer genome atlas data	Song Xu	Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, China
FP2-28	The Role of psychological intervention in lung cancer patients receiving radical thoracic radio(chemo)therapy	Yang Haixia	Department of Radiotherapy, The Second Affiliated Hospital of the Air Force Medical University, China
FP2-29	Genomic sequencing and editing revealed the GRM8 signaling pathway as potential therapeutic targets of squamous cell lung cancer	Zhang P. Panpan	Thoracic Surgery II, Peking University Cancer Hospital & Institute, China
FP2-30	Identification and validation of a prognostic signature in malignant pleural mesothelioma	Zhou Jian-guo	Thoracic Oncology, Department of Oncology, Affiliated Hospital of Zunyi Medical University, China
FP2-31	Ideal screening model for the primary cervical cancer screening program in country with high prevalence of cervical cancer	Taejong Song	Gynecologic Oncology, Department of Obstetrics & Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea
FP2-32	Current status of treatment of uterine cervical cancer at our department	Akiko Abe	Obstetrics and Gynecology, Tokushima University Hospital, Japan
FP2-33	A new novel gene ABCC5 promotes castration-resistant prostate cancer progression through ERK carcinogenic pathway	Guangjie Ji	Department of Urology, Peking University First Hospital, China